Post-marketing safety surveillance of Amivantamab: a real world study based on the FDA adverse event reporting system. - Fu X; Zeng D; Li M; Wu J; Yang Y; Mao Q; Qiu W; Huang X; Fang Y; Jiang L; Hu P; Liao W (Expert opinion on drug safety, 2026)